Get the Stockscreener App
164.83
2.49%
4.00
Krystal Biotech Inc stock is traded at $164.83, with a volume of 702.67K.
It is up +2.49% in the last 24 hours and down -7.45% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$160.83
Open:
$159.2
24h Volume:
702.67K
Relative Volume:
2.95
Market Cap:
$4.74B
Revenue:
$241.52M
Net Income/Loss:
$52.37M
P/E Ratio:
-112.13
EPS:
-1.47
Net Cash Flow:
$58.06M
1W Performance:
+0.73%
1M Performance:
-7.45%
6M Performance:
-3.73%
1Y Performance:
+45.94%
1-Day Range:
$159.20
$165.98
1-Week Range:
$155.16
$176.59
52-Week Range:
$107.50
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
164.83 | 4.74B | 241.52M | 52.37M | 58.06M | 1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech reports success with inhalable lung cancer drug in early-stage trial - Mugglehead
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707 - Yahoo Finance
Geode Capital Management LLC Purchases 11,411 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer - Marketscreener.com
Krystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at Chardan Capital - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Shares Gap UpStill a Buy? - MarketBeat
Krystal Biotech Reports Positive Results for KYANITE-1 Study - TipRanks
Krystal Biotech (NASDAQ:KRYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Krystal Biotech reports promising lung cancer trial results - Investing.com
Krystal Biotech reports promising lung cancer trial results By Investing.com - Investing.com UK
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Franklin Resources Inc. Has $43.77 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Teachers Retirement System of The State of Kentucky Increases Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
KRYS Reports Upbeat Initial Data From Lung Cancer Study Of KB707 - Barchart
Lord Abbett & CO. LLC Sells 108,079 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech CEO Krishnan sells shares worth $4.12 million By Investing.com - Investing.com South Africa
Krystal Biotech's president Suma Krishnan sells $8.2 million in stock By Investing.com - Investing.com South Africa
Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech CEO Krishnan sells shares worth $4.12 million - Investing.com
Krystal Biotech's president Suma Krishnan sells $8.2 million in stock - Investing.com
KRYS Stock Down On Initial Clinical Updates On KB407 & KB408 - Barchart
KRYS Stock Down on Initial Clinical Updates on KB407 & KB408 - MSN
Krystal Biotech announces initial update for KB408, KB407 - Yahoo Finance
Expert Ratings For Krystal Biotech - Benzinga
Krystal Biotech Reports Promising Results for Genetic Medicine - TipRanks
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels - The Manila Times
Krystal Biotech, Inc. Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 - Marketscreener.com
State Street Corp Purchases 119,936 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS) - MarketBeat
Krystal Biotech expects EMA opinion on DEB treatment in 1Q 2025 - Investing.com Nigeria
Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa - The Manila Times
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa - Marketscreener.com
Krystal Biotech's B-VEC Advances Toward EU Approval: No Major Objections from EMA for Rare Disease Treatment - StockTitan
BNP Paribas Financial Markets Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Main Management ETF Advisors LLC Purchases New Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Brokerages - MarketBeat
The Manufacturers Life Insurance Company Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Why Is Krystal Biotech (KRYS) Up 6.6% Since Last Earnings Report? - MSN
Redmile Group LLC Has $147.49 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
(KRYS) Investment Report - Stock Traders Daily
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Erste Asset Management GmbH Buys Shares of 18,200 Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Citigroup Inc. Raises Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Eventide Asset Management LLC Has $17.44 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Braidwell LP Buys 61,512 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
KRYS (Krystal Biotech) Other Long Term Assets : $0.2 Mil (As of Sep. 2024) - GuruFocus.com
Fmr LLC Purchases 9,115 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat
Krystal Biotech to Present at Upcoming Investor Conferences - The Manila Times
Krystal Biotech CEO to Present at Citi and Evercore Healthcare Conferences | KRYS Stock News - StockTitan
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):